GRAIL (NASDAQ:GRAL) Trading 7.2% Higher - Should You Buy?

Key Points

• GRAIL, Inc. shares rose 7.2% during mid-day trading, reaching a high of $45.35 after closing at $41.65 previously.
• The company reported a loss of ($3.18) earnings per share for the last quarter, missing analyst expectations, and had a revenue of $35.54 million compared to estimates of $37.57 million.
• Major insider sales included Chun R. Ding selling 339,800 shares valued at approximately $16.83 million, reducing their position by 9.32%.

GRAIL, Inc. (NASDAQ:GRAL - Get Free Report) shares rose 7.2% during mid-day trading on Monday . The stock traded as high as $45.35 and last traded at $44.66. Approximately 335,616 shares were traded during mid-day trading, a decline of 74% from the average daily volume of 1,279,298 shares. The stock had previously closed at $41.65.

GRAIL Stock Performance

The stock has a market cap of $1.61 billion, a P/E ratio of -3.41 and a beta of 3.18. The company has a 50-day simple moving average of $35.34 and a 200-day simple moving average of $35.50.

GRAIL (NASDAQ:GRAL - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($3.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.14) by ($0.04). GRAIL had a negative net margin of 329.86% and a negative return on equity of 16.64%. The business had revenue of $35.54 million during the quarter, compared to analyst estimates of $37.57 million. As a group, sell-side analysts expect that GRAIL, Inc. will post -15.15 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, major shareholder Chun R. Ding sold 339,800 shares of GRAIL stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $49.53, for a total value of $16,830,294.00. Following the completion of the transaction, the insider directly owned 3,305,055 shares of the company's stock, valued at approximately $163,699,374.15. This trade represents a 9.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Aaron Freidin sold 8,000 shares of the business's stock in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $38.93, for a total value of $311,440.00. Following the completion of the sale, the chief financial officer directly owned 286,020 shares of the company's stock, valued at $11,134,758.60. The trade was a 2.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 361,694 shares of company stock valued at $17,780,266. 1.85% of the stock is currently owned by company insiders.

Institutional Trading of GRAIL

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of GRAIL by 3.4% during the first quarter. Vanguard Group Inc. now owns 1,499,740 shares of the company's stock valued at $38,303,000 after purchasing an additional 48,645 shares during the last quarter. AQR Capital Management LLC grew its position in GRAIL by 61.0% in the 1st quarter. AQR Capital Management LLC now owns 1,337,163 shares of the company's stock worth $33,991,000 after purchasing an additional 506,440 shares during the period. Geode Capital Management LLC grew its position in GRAIL by 60.4% in the 2nd quarter. Geode Capital Management LLC now owns 757,770 shares of the company's stock worth $38,969,000 after purchasing an additional 285,331 shares during the period. Wealthquest Corp bought a new stake in GRAIL in the 1st quarter worth approximately $18,247,000. Finally, Bank of New York Mellon Corp grew its position in GRAIL by 7.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 350,979 shares of the company's stock worth $18,047,000 after purchasing an additional 25,548 shares during the period.

GRAIL Company Profile

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.